Targeting the PI3K pathway in cancer: are we making headway? (Q52672314)

5 May 2018

title

Targeting the PI3K pathway in cancer: are we making headway? (English)

1 reference

5 May 2018

3

Funda Meric-Bernstam

1 reference

5 May 2018

1

Filip Janku

1 reference

5 May 2018

Timothy A Yap

2

1 reference

5 May 2018

language of work or name

English

0 references

publication date

6 March 2018

1 reference

5 May 2018

Nature Reviews Clinical Oncology

published in

1 reference

5 May 2018

volume

15

1 reference

5 May 2018

page(s)

273-291

1 reference

5 May 2018

issue

5

1 reference

5 May 2018

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Targeting the phosphoinositide 3-kinase pathway in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

PI3K and cancer: lessons, challenges and opportunities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Drugging PI3K in cancer: refining targets and therapeutic strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

AKT Inhibition in Solid Tumors With AKT1 Mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Genome sequencing identifies a basis for everolimus sensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Response and acquired resistance to everolimus in anaplastic thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Development of PI3K inhibitors: lessons learned from early clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

mTOR Signaling in Growth, Metabolism, and Disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Autophagy as a target for anticancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Everolimus for advanced pancreatic neuroendocrine tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

mTOR and cancer: insights into a complex relationship

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, pla

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

PI3K in lymphocyte development, differentiation and activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

PI3Kgamma (PI3Kgamma) is essential for efficient induction of CXCR3 on activated T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Take (STAT)5: jazzing up T-cell leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity of β-thalassemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Adaptive Randomization of Neratinib in Early Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Biomarkers of response to Akt inhibitor MK-2206 in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Subclonal diversification of primary breast cancer revealed by multiregion sequencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Tracking the Evolution of Non-Small-Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2018.28

inferred from DOI database lookup

7 January 2021

based on heuristic

Phase II study of PX-866 in recurrent glioblastoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29508857

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29508857

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2018.28

1 reference

5 May 2018

PubMed ID

29508857

1 reference

5 May 2018